Clinical Map Initiative

Launched in February 2014, Regulus’ ‘Clinical Map Initiative’ outlines certain corporate goals to advance its microRNA therapeutics pipeline over the next several years. »

CLINICAL TRIALS Athena - Mapping the course of Alport Syndrome

We are currently enrolling patients for the natural history of disease study for RG-012 for Alport syndrome. More information about ATHENA enrolling locations and patient eligibility requirements can be found here.

MORE INFORMATION HERE»

shell
Enter the Portal